Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection.
BMJ Case Rep
; 15(7)2022 Jul 28.
Article
in English
| MEDLINE | ID: covidwho-1962124
ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that may be triggered by inflammation, including infection or vaccination. Since the start of the COVID-19 pandemic, several case reports were published on de novo or relapsed immune TTP (iTTP) in COVID-19-infected patients. Case reports of iTTP episodes following vaccination against COVID-19 are also emerging. We report a case of relapsed iTTP in a patient who received Moderna mRNA-1273 SARS-CoV-2 vaccine and developed concurrent severe COVID-19 infection. The patient's iTTP was successfully managed with caplacizumab, therapeutic plasma exchange and high-dose steroids. We summarise published cases of iTTP associated with COVID-19 infection or vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Purpura, Thrombotic Thrombocytopenic
/
Purpura, Thrombocytopenic, Idiopathic
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Case report
/
Observational study
Topics:
Vaccines
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Bcr-2021-247524
Similar
MEDLINE
...
LILACS
LIS